Atlas Trials

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Clinical trial NCT00082784 · COMPLETED

Trial details

NCT number
NCT00082784
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueNodal Marginal Zone LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRefractory Plasma Cell MyelomaSplenic Marginal Zone Lymphoma
Start date
2004-03-01
Primary completion
2012-10-01
Enrollment
93

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.